Experimental Hematology and Cancer Biology

Experimental Hematology and Cancer Biology Research

The Division of Experimental Hematology and Cancer Biology is committed to hematology, cancer and gene therapy research and strives to understand the biology of blood cell formation and function and to dissect cancer etiology and pathology.

Our findings can be used in the development of innovative treatments of genetic and acquired diseases affecting the blood system and cancer. Research efforts are allocated in six basic research programs within the division, optimizing the potential for translational research that can help children with genetic blood diseases, immunodeficiencies, cancers and leukemia.

The Division of Experimental Hematology and Cancer Biology has a close and specialized relationship with the Cancer and Blood Diseases Institute at Cincinnati Children’s. This relationship enhances two-way translational research and leads to more innovation in both clinical trials and delivery of care. The partnership also serves to enhance institutional utilization of gene therapy modalities in the treatment of devastating pediatric diseases.

Together with the Cancer and Blood Diseases Institute, we aim to develop a world-class clinical / translational / research program in pediatric cancer and blood diseases. The collaboration provides a unique opportunity for faculty, fellows, staff and patients to experience the combined benefits of focused clinical and research programs.

The Division of Experimental Hematology and Cancer Biology is part of the Cancer and Blood Diseases Institute. The institute also includes the Divisions of Bone Marrow Transplantation and Immune Deficiency, Hematology and Oncology.

The director of the Division of Experimental Hematology and Cancer Biology is Yi Zheng, PhD.